#Phase3clinicaltrial
LightNews LightNews
4040rec.bsky.social
#Haematology #oncology #Takeda #NICErecommended #brentuximabvedotin #AVD #brentuximabvedotinplusAVD #Hodgkinlymphoma #stage3Hodgkinlymphoma #stage4Hodgkinlymphoma #Hodgkinlymphomapatients #NICEdecision #phase3clinicaltrial #ECHELON1trial l
pharmatimes.com/news/nice-re...
NICE recommends brentuximab vedotin plus AVD for Hodgkin lymphoma - PharmaTimes
Advancing care for stage 3 or 4 Hodgkin lymphoma patients
pharmatimes.com
April 3, 2025 at 10:05 AM
nile11.bsky.social
FDA Approves Moderna’s First mRNA Seasonal Flu Vaccine mFlusiva
#i#influenzaikeIllness #m#mflusivam#modernaInc#m#mrna010 #p#phase3ClinicalTrialr#richardHughesIvs#seasonalInfluenzaVaccineu#u.FoodAndDrugAdministration #w#worldHealthOrganizationn#nile1
FDA Approves Moderna’s First mRNA Seasonal Flu Vaccine mFlusiva
The U.S. Food and Drug Administration has approved Moderna Inc.’s seasonal influenza vaccine mFlusiva for adults aged 50 and older, marking the first
nile1.com
August 6, 2026 at 8:55 AM
4040rec.bsky.social
#NICE #Roche #lupusdrug #lupus #lupusnephritis #systemiclupuserythematosus #SLE #kidneyfunction #Gazyvaro #obinutuzumab #NHS #kidneydisease #autoimmunedisorder #antiCD20antibody #NICEdraftrecommendation #Clinicaltrials #MMF #phase3clinicaltrial #ALLEGORYtrial #LupusUK #HEOR
zurl.co/cH0ta
NICE backs Roche lupus drug that supports kidney function
Roche's Gazyvaro, a drug that can restore kidney function in lupus nephritis, has been cleared for use by the NHS in England and Wales.
pharmaphorum.com
February 4, 2026 at 10:15 AM
4040rec.bsky.social
#Ultrarapidinsulin #phase3trial #type1diabetes #BioChaperoneLispro #THDB0206injection #postmealglucosecontrol #TonghuaDongbao #phase3clinicaltrial #ultrarapidinsulinformulation #HbA1creduction #bloodglucose #selfmonitoringbloodglucose #SMBG #diabetes #obesity
zurl.co/nlXjK
Ultra-rapid insulin shows promise in phase 3 trial for type 1 diabetes - PharmaTimes
BioChaperone Lispro demonstrates improved post-meal glucose control compared to Humalog
zurl.co
October 22, 2025 at 8:16 AM
4040rec.bsky.social
#digitalhealth #mentalhealth #BoehringerIngelheim #DTx #schizophrenia #phase3clinicaltrial #digitaltherapeutics #smartphonebasedapp #CT155app #ClickTherapeutics #CONVOKEstudy #CONVOKE #prescriptiondigitaltherapeutic #CAINSMAP #CT155 #antipsychotics #breakthroughdevicestatus
zurl.co/cndtD
Click, Boehringer DTx for schizophrenia passes phase 3 test
Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app
zurl.co
August 12, 2025 at 8:53 AM
4040rec.bsky.social
#dermatology #immunology #UCB #SMC #SMCapprovel #bimekizumab #hidradenitissuppurativa #HS #hidradenitissuppurativatreatment #ScottishMedicinesConsortium #NHSScotland #HSpatients #phase3clinicaltrial #BEHEARDI #BEHEARDII #clincialstudies #patientoutcomes
pharmatimes.com/news/smc-app...
SMC approves bimekizumab for hidradenitis suppurativa treatment - PharmaTimes
The Scottish Medicines Consortium (SMC) has approved bimekizumab for adults with active moderate to severe hidradenitis suppurativa (HS) who have not
pharmatimes.com
April 7, 2025 at 11:12 AM
4040rec.bsky.social
#oncology #Amivantamab #lazertinib #lungcancer #Janssen #phase3clinicaltrial #MARIPOSAstudy #EGFRmutatedadvancednonsmallcelllungcancer #NSCLC #nonsmallcelllungcancer #Rybrevant #Lazcluze #EuropeanLungCancerCongress #lungcancertreatment #patientoutcomes
pharmatimes.com/news/amivant...
Amivantamab plus lazertinib shows survival benefit in lung cancer - PharmaTimes
Janssen drug combination extends life expectancy during trial
pharmatimes.com
April 1, 2025 at 9:46 AM
4040rec.bsky.social
#CSL #CSLBehring #garadacimab #hereditaryangioedema #HAE #HAEpatients #EMA #CHMP #factorXIIainhibitor #HAEattacks #CHMPdecision #HAEattacks #HAEattackprevention #Phase3clinicaltrial #VANGUARDclinicaltrial #openlabelextensionstudy
pharmatimes.com/news/csl-rec...
CSL receives positive opinion for garadacimab in hereditary angioedema - PharmaTimes
New treatment could revolutionise care for HAE patients
pharmatimes.com
December 16, 2024 at 3:29 PM
kstrategyand.bsky.social
www.linkedin.com/pulse/dermat...

Dermata’s Xyngari(TM) Set to Transform Acne Treatment with FDA Approval

kstrategyand.com/pharma-news

#DermataTherapeutics #Xyngari #FDAApproval #AcneTreatment #BiotechInnovation #Phase3ClinicalTrial #SkincareResearch #Humanteconomy #Humantec #KStrategyand
Dermata’s Xyngari(TM) Set to Transform Acne Treatment with FDA Approval
Dermata Therapeutics has received FDA approval for the proprietary name "Xyngari" (formerly DMT310), a significant milestone for the biotechnology company. Xyngari is a cutting-edge product currently ...
www.linkedin.com
January 9, 2025 at 10:17 AM